Continuing its search for ophthalmic drivers, Novartis AG has in-licensed a recombinant human lubricin from Lµbris BioPharma which it hopes will become a solution for dry eye, a condition with high unmet medical need that affects more than 344 million patients globally.
The in-licensing arrangement for the product, dubbed ECF843, was announced April 6 and gives the Swiss drug maker commercial rights to it outside the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?